Gerresheimer stock steadies near 26 euros as AGM and growth figures shape expectations

Published on 09/02/2026 at 07:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gerresheimer stock is trading close to its late August Xetra closing level while investors digest the virtual annual general meeting and updated revenue and EBITDA figures for 2024 and 2025.

Automatisierte Glasampullen-Produktionslinie in steriler Pharmafabrik — Gerresheimer AG mit ISIN DE000A0LD6E6 produziert Glasampullen in hochautomatisierter, steriler Pharmaverpackungsfertigung mit modernster Anlagentechnik, Illustration mit AI erstellt.

Gerresheimer AG (ISIN DE000A0LD6E6) stock is currently trading close to its recent Xetra closing level of 26.62 EUR as of August 28, 2026, giving investors a stable reference point ahead of fresh quarterly figures in mid October 2026.

AGM decisions and DACH context

According to an EQS corporate news release dated September 1, 2026, Gerresheimer held its annual general meeting virtually in Duesseldorf, with shareholders approving the companys proposed resolutions by a majority vote.

The company is listed on the Frankfurt Stock Exchange and trades on Xetra under the ticker GXI, giving it direct visibility among DACH investors who follow the German mid cap and healthcare supplier segment.

Revenue growth and EBITDA trends

For the most recently reported fiscal year 2025, a summary of the AGM presentation compiled by Quartr on September 1, 2026 indicates that revenue rose to EUR 2,321,000,000, an increase of 17 percent compared with corrected fiscal year 2024 revenue of EUR 1,991,000,000.

Over the same period, adjusted EBITDA slipped slightly from EUR 388,000,000 in 2024 to EUR 384,000,000 in 2025, highlighting that while the top line benefited strongly from the Bormioli Pharma acquisition, margins came under pressure.

The presentation notes that revenue including Bormioli Pharma rose by 19.6 percent, underlining the scale of the acquisition contribution but also explaining why management revised the 2025 outlook downward despite the double digit revenue growth.

Q1 2026 cash flow improvement

The same AGM material summarized by Quartr reports that in Q1 2026 Gerresheimer delivered slight revenue growth versus the prior year quarter while achieving a significant improvement in free cash flow, driven by tighter capital expenditure and inventory management.

For investors, this combination of moderate revenue expansion and stronger cash generation in Q1 2026 is important because it suggests that the company is moving from a phase dominated by acquisition integration toward a more disciplined balance sheet and cash flow focus.

Management emphasized transformation, compliance and portfolio focus as key drivers of the financial recovery and future growth pathway, reinforcing the message that operational discipline is now central to the story after the internal investigations and corrections that affected the 2024 baseline figures.

Go deeper

More data and news on Gerresheimer stock

Investors can find additional quotes, charts and company news on Gerresheimer stock as well as regulatory filings and corporate actions in the dedicated topic overview.

Gerresheimer stock overview on ad-hoc-news.de Investor Relations

Product focus: pharmaceutical primary packaging

Gerresheimer is best known for its pharmaceutical primary packaging solutions such as glass vials and syringes used to store and administer injectable medications, a segment that has benefited from rising biologics and vaccine volumes in recent years.

In the context of the Bormioli Pharma acquisition highlighted in the AGM presentation, the company has strengthened its position in high value added plastic and glass packaging for prescription medicines, expanding its customer base among international pharmaceutical manufacturers.

For retail investors, the packaging portfolio is relevant because it anchors Gerresheimer in a defensive healthcare supply chain niche where long term contract relationships and regulatory requirements can support steady demand even in volatile macroeconomic conditions.

Stock price level and upcoming earnings date

Market data compiled by MarketScreener for the Xetra listing shows a last closing price of 26.62 EUR for Gerresheimer stock on August 28, 2026, with a daily gain of 0.38 percent and trading volume of 166,376 shares on that date.

The same overview indicates that the stock is down 3.55 percent over the past five trading days and 3.48 percent since the start of 2026, a reminder that despite the recent stabilization around 26 euros the longer term trend has been slightly negative.

Investors will next receive a more detailed operating update when Gerresheimer publishes its Q3 2026 results, which MarketScreener lists with a scheduled release date of October 14, 2026, making that mid October reporting day a key catalyst for reassessing the revenue, margin and cash flow trajectory.